HyperRAB Patient Counseling Information

Discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient.
Inform the patient who is allergic to human immune globulin products that severe, potentially life-threatening allergic reactions could occur [see Hypersensitivity Reactions under Precautions].
Inform the patient who is deficient in IgA the potential for developing anti-IgA antibodies and severe potentially life-threatening allergic reactions [see Hypersensitivity Reactions under Precautions].
Inform the patient that HYPERRAB is made from human plasma and may carry a risk of transmitting infectious agents that can cause disease. While the risk that HYPERRAB can transmit an infectious agent has been reduced by screening plasma donors for prior exposure, testing donated plasma, and including manufacturing steps with the capacity to inactivate and/or remove pathogens, the patient should report any symptoms that concern them [see Transmissible Infectious Agents under Precautions].